Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAlterity Therapeutics Ltd

Alterity Therapeutics Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.27 AUD -0.03 ( 10.00%)
Last update at 2026-11-10T05:10:00Z
VOLUME
231920
Market Cap
60.71M

Momentum Score

…

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.27
Low
0.30
High
52 Week Price Range
0.23
Low
0.79
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Alterity Therapeutics is a clinical-stage Australian biotechnology company developing small-molecule therapies that target metal dysregulation and alpha-synuclein aggregation in neurodegenerative diseases, with lead candidate ATH434 focused on Parkinsonian disorders and related synucleinopathies. Long-term growth may be driven by clinical progress for ATH434, biomarker-guided development and potential licensing or partnering opportunities that could support advancement toward disease-modifying treatments.

Key investment risks include high clinical and regulatory failure probability, ongoing financing needs that may dilute shareholders, and significant competition from other neurodegenerative drug programs.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.30
Dividend Yield
-
Revenue TTM
3.61M
Revenue Per Share
0.02
Gross Profit TTM
3.35M
Debt / Equity
0.00
ROE
-54.98%
Net Debt
-37.12M
ROCE
-66.30%
Diluted EPS TTM
-0.11

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -26.90M -12.08M -19.08M -13.70M -12.78M
Net income -23.40M -12.15M -19.12M -13.81M -12.85M
Selling general administrative - 5.48M 4.77M 4.94M 5.46M
Selling and marketing expenses - - -0.01M 0.05M -
Gross profit -0.12M 5.31M 3.80M 3.63M -
Reconciled depreciation - 0.14M 0.15M 0.10M 0.05M
Ebit -28.42M -14.66M -19.61M -15.29M -17.86M
Ebitda -28.30M -14.63M -19.46M -15.19M -17.81M
Depreciation and amortization 0.12M 0.03M 0.15M 0.10M 0.05M
Operating income -28.42M -14.57M -19.60M -14.64M -17.86M
Other operating expenses 28.42M 20.01M 23.62M 14.35M 15.14M
Interest expense - - - - 0.00M
Tax provision - 0.07M 0.05M 0.10M 0.07M
Interest income - 0.45M 0.27M 0.02M 0.00M
Net interest income - 0.45M 0.27M 0.02M 0.00M
Income tax expense -3.50M 0.07M 0.05M 0.10M 0.07M
Total revenue - 5.44M 4.02M 3.92M 0.00M
Total operating expenses 28.30M 19.89M 23.41M 14.35M 15.14M
Cost of revenue 0.12M 0.13M 0.21M 0.29M -
Total other income expense net 1.52M 2.49M 0.52M 0.65M 5.08M
Net income from continuing ops - -12.15M -19.12M -13.81M -12.85M
Net income applicable to common shares - -12.15M -19.12M -13.81M -12.85M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 46.02M 46.03M 19.22M 27.32M 41.36M
Other current assets 0.81M 0.04M 2.36M 0.04M 0.01M
Total liab 3.29M 3.62M 5.43M 4.50M 5.89M
Total stockholder equity 42.72M 42.40M 13.80M 22.81M 35.47M
Other current liab 1.98M 0.00M 4.67M 2.67M -0.03M
Common stock 282.51M - 223.15M 213.97M 213.79M
Capital stock - 262.95M - 213.97M 213.79M
Retained earnings -245.58M -225.89M -214.16M -195.13M -181.88M
Other liab - - - 0.02M 0.01M
Other assets - - 0.00M - -
Cash 37.32M 33.16M 12.64M 15.77M 34.81M
Cash and equivalents - - - - 34.81M
Total current liabilities 3.16M 3.53M 5.37M 4.38M 5.82M
Current deferred revenue - - 0.02M -0.11M 3.10M
Net debt -37.12M - -12.48M -15.56M -34.69M
Short term debt 0.06M - 0.11M 0.11M 0.06M
Short long term debt total 0.19M - 0.16M 0.21M 0.12M
Other stockholder equity - - - -18.84M -31.90M
Property plant equipment - - - 0.27M 0.22M
Total current assets 45.83M 45.87M 19.04M 27.05M 41.14M
Net tangible assets - - - 22.81M 35.47M
Short term investments - 7.50M - - -
Net receivables 7.70M - 4.04M 8.67M 4.73M
Inventory - - 0.00M 2.57M 1.60M
Accounts payable 1.12M 0.54M 0.58M 1.72M 2.69M
Accumulated other comprehensive income 5.80M - 4.81M - 3.57M
Non currrent assets other - - -0.00M -0.27M -0.22M
Non current assets total 0.19M 0.16M 0.19M 0.27M 0.22M
Capital lease obligations - 0.16M - 0.21M 0.12M
Long term debt total - - - - 0.06M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -7.50M -0.01M -0.01M -0.09M
Change to liabilities - - - -1.56M 2.60M
Total cashflows from investing activities 7.50M -7.50M -0.01M -0.04M -0.09M
Net borrowings - -0.13M -0.01M -0.06M -0.03M
Total cash from financing activities 19.13M 39.67M 9.22M 0.12M 16.30M
Change to operating activities - - - -0.89M -0.39M
Net income -23.40M -12.15M -19.12M -13.81M -12.85M
Change in cash 4.16M 20.52M -3.13M -19.03M 6.69M
Begin period cash flow 33.16M 12.64M 15.77M 34.81M 28.12M
End period cash flow 37.32M 33.16M 12.64M 15.77M 34.81M
Total cash from operating activities -22.52M -11.45M -12.61M -20.04M -12.34M
Issuance of capital stock - 42.57M 10.14M 0.31M 17.18M
Depreciation 0.12M 0.14M 0.15M 0.10M 0.05M
Other cashflows from investing activities - -7.50M 0.00M -0.03M -0.03M
Dividends paid - - - 0.00M 0.00M
Change to inventory - - - 2.45M -2.21M
Change to account receivables -3.76M 0.10M 4.62M -3.94M -0.45M
Sale purchase of stock - 42.57M 10.14M 0.32M 17.18M
Other cashflows from financing activities -0.14M -2.77M -0.92M -0.13M -0.84M
Change to netincome - - - 0.06M -1.31M
Capital expenditures 22.52M 0.00M 0.01M 0.01M 0.09M
Change in working capital -3.70M -0.61M 5.75M -3.94M -0.45M
Stock based compensation - 0.98M 0.88M 0.97M 1.51M
Other non cash items 4.46M 0.19M -0.26M -6.35M 0.46M
Free cash flow - -11.45M -12.61M -20.04M -12.43M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ATH
Alterity Therapeutics Ltd		 -0.03
10.00%		 0.27 - 10.33 16.82 1.55 164.75 1.13
CSL
CSL Ltd		 -0.04
0.02%		 200.73 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.13
0.93%		 13.80 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 0.36
1.51%		 24.20 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 0.04
1.96%		 2.08 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Alterity Therapeutics Ltd

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.

500 Collins Street, Melbourne, VIC, Australia, 3000

61 3 9349 4906

https://alteritytx.com

11

Name Title Year Born
Mr. Geoffrey Paul Kempler B.Sc, B.Sc. Co-Founder & Non-Exec. Chairman 1955
Dr. David A. Stamler M.D. Chief Exec. Officer 1961
Ms. Kathryn J. E. Andrews Chief Financial Officer 1967
Dr. Rudolph Emile Tanzi Ph.D. Chief Scientific Advisor and Member of R&D Advisory Board 1958
Dr. Steven D. Targum Chief Medical Advisor NA
Dr. Robert Cherny Head of Research NA
Mr. Phillip Allen Hains BBus(Acc), CA, MBA Company Sec. 1959
Mr. Geoffrey Paul Kempler B.Sc. Co-Founder & Non-Executive Chairman 1955
Dr. David A. Stamler M.D. Chief Executive Officer 1961
Ms. Kathryn J. E. Andrews B.Com, CPA Chief Financial Officer 1967

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

QTWO
CAD 1.78
+10.56%
NEO
CAD 27.77
+5.91%
CGI
CAD 52.81
+4.78%
PET
CAD 22.34
+3.81%
QBR-A
CAD 77.96
+2.40%
GFL
CAD 57.98
-10.54%
MUX
CAD 21.12
-7.53%
BYN
CAD 1.58
-7.06%
BRVO
CAD 2.23
-6.89%
ITR
CAD 3.12
-6.87%

Equity Sectors*

  • Basic Materials

    -4.26%

  • Communication Services

    +0.36%

  • Consumer Cyclical

    -0.62%

  • Consumer Defensive

    -0.33%

  • Energy

    -0.09%

  • Financial Services

    -0.18%

  • Healthcare

    -1.69%

  • Industrials

    -1.10%

  • Real Estate

    -0.83%

  • Technology

    -0.67%

  • Utilities

    +0.31%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…